FLT3 and acute myeloid leukemia: Previous reports have shown that second generation bis-aryl urea FLT3 inhibitor, quizartinib, potently inhibits ABCG2 at clinically used concentrations and thus may sensitize AML cells overexpressing ABCG2 transporter to ABCG2 substrate anticancer drugs [25, 28].